Replimune Group, Inc. - REPL STOCK NEWS

Replimune presented primary analysis data from the IGNYTE clinical trial evaluating RP1 combined with nivolumab in anti-PD1 failed melanoma patients at SITC 2024. The trial included 140 patients with a median follow-up of 15.4 months. Key results showed an overall response rate of 33.6% by mRECIST criteria, with a 15% complete response rate. The median duration of response was 21.6 months, with one-, two-, and three-year survival rates of 75.3%, 63.3%, and 54.8%, respectively. Biomarker data demonstrated increased CD8+ T cell and PD-L1 expression, indicating potential for generating anti-tumor immune responses. The treatment was well-tolerated with mostly Grade 1-2 adverse events.

Replimune Group announced inducement equity awards to 12 newly hired non-executive employees. The awards include non-qualified stock options to purchase 19,390 shares at $12.02 per share and restricted stock units representing 38,810 shares. The options have a 10-year term with 25% vesting after one year and the remainder monthly over three years. The restricted stock units vest in four annual installments starting November 15, 2025. These awards were approved under Nasdaq Listing Rule 5635(c)(4) and align with the Company's 2018 Equity Incentive Plan terms.

Replimune Group (NASDAQ: REPL) announced two key presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024) in Houston, Texas. The first is a late-breaking oral presentation featuring primary analysis data from the IGNYTE clinical trial, including subgroup and initial biomarker analyses of RP1 plus nivolumab in anti-PD1 failed melanoma patients. Dr. Michael K. Wong from MD Anderson Cancer Center will present this on November 9, 2024.

Additionally, Dr. Diwakar Davar from UPMC Hillman Cancer Center will present an encore poster on November 8, 2024, sharing data from the ARTACUS clinical trial, which studied RP1 monotherapy in solid organ transplant patients with advanced cutaneous malignancies.

Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company, has announced the grant of inducement equity awards to 9 newly hired non-executive employees. The awards include:

- Non-qualified stock options to purchase 8,870 shares of common stock
- Restricted stock units representing 17,745 shares of common stock

The stock options have an exercise price of $11.33 per share, equal to the closing price on October 7, 2024. They have a 10-year term and will vest over four years. The restricted stock units vest in approximately four equal annual installments beginning on November 15, 2025.

These inducement awards were approved by the compensation committee under Nasdaq Listing Rule 5635(c)(4) and will have terms consistent with the Company's 2018 Equity Incentive Plan.

Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company focused on developing novel oncolytic immunotherapies, has announced its participation in two upcoming investor conferences. The company's management team will be presenting and hosting investor meetings at these events:

1. BMO 2024 Oncology Summit on Tuesday, October 8, 2024

2. 3rd Annual Roth Healthcare Opportunities Conference on Wednesday, October 9, 2024

These conferences provide Replimune with an opportunity to showcase its progress in the field of oncolytic immunotherapies and engage with investors. The company's presence at these events underscores its commitment to advancing its clinical-stage pipeline and maintaining open communication with the investment community.

Replimune Group (NASDAQ: REPL) presented primary analysis data from the IGNYTE clinical trial of RP1 combined with nivolumab in anti-PD1 failed melanoma at ESMO Congress 2024. The trial included 140 patients who received RP1 plus nivolumab after confirmed progression on anti-PD1 based therapy. Key results include:

- Overall response rate (ORR) of 33.6% by mRECIST and 32.9% by RECIST 1.1
- Complete response rate of 15% by mRECIST
- ORR of 27.7% in patients with prior anti-PD1 and anti-CTLA-4 treatment
- Median duration of response from treatment initiation was 27.6 months
- One-, two-, and three-year survival rates were 75.3%, 63.3%, and 54.8% respectively

The treatment was well-tolerated with mostly Grade 1-2 adverse events. Replimune plans to submit a BLA for RP1 in anti-PD1 failed melanoma in the second half of 2024.

Replimune Group, Inc. (NASDAQ: REPL) has successfully completed a pre-Biologics License Application (pre-BLA) meeting with the FDA, supporting their plans to submit a BLA for RP1 (vusolimogene oderparepvec) in the treatment of anti-PD1 failed melanoma via the accelerated approval pathway in 2H 2024. The company's CEO, Sushil Patel, confirmed that the accelerated approval path is available for RP1 in this indication. Topline results from the primary analysis of the IGNYTE clinical trial of RP1 plus nivolumab showed an overall response rate of 33%. Independently reviewed data from this trial, including key secondary endpoints and subgroup analyses, will be presented at the ESMO Annual Congress 2024 in Barcelona on September 15, 2024.

Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company, announced the election of Madhavan (Madhu) Balachandran to its Board of Directors at the annual stockholders meeting. Balachandran brings over 40 years of experience in manufacturing and operations to Replimune's board. He previously served as Executive Vice President of Operations at Amgen Inc., overseeing global operations. CEO Sushil Patel expressed enthusiasm about Balachandran's addition, citing his valuable experience in commercial development, manufacturing, and operations as assets for Replimune's commercialization preparations. Balachandran's background includes senior operations positions at Burroughs Wellcome Co. and an extensive educational background in chemical engineering and business administration.

Replimune Group (NASDAQ: REPL) announced that a late-breaking abstract presenting the primary analysis of the IGNYTE clinical trial has been selected for oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024. The presentation, titled 'Primary efficacy, safety, and survival data from the registration-intended cohort of patients with anti-PD-1-failed melanoma from the IGNYTE clinical trial with RP1 combined with nivolumab,' will be delivered by Dr. Caroline Robert from Gustave Roussy Cancer Center on September 15, 2024. This presentation is part of the Mini Oral Session on Melanoma and other skin tumors, highlighting Replimune's progress in developing novel oncolytic immunotherapies.